- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.03. | Blackstone puts $400M into Teva, Sanofi gut disease drug | ||
| 04.03. | Prime to test FDA flexibility with 2-patient gene editing submission | ||
| 04.03. | FDA again targets GLP-1 compounders; Intellia to restart heart disease trial | ||
| 03.03. | Kyowa Kirin abandons touted eczema drug following safety review | ||
| 03.03. | Pierre Fabre seeks to revive US approval chances for spurned cell therapy | ||
| 02.03. | Candid Therapeutics, in a reverse merger with RallyBio, to go public | ||
| 02.03. | Ascendis wins FDA approval of dwarfism drug | ||
| 02.03. | UniQure says FDA wants another study of Huntington's gene therapy | ||
| 02.03. | Roche pill succeeds in another MS study, but approval questions linger | ||
| 02.03. | Safety concerns spur Aardvark to halt key Prader-Willi drug trial | ||
| 02.03. | Why it's critical to close open steps in cell therapy manufacturing | ||
| 27.02. | Atrium Therapeutics spins out of Avidity, aiming to target rare heart diseases with RNA | ||
| 27.02. | UniQure falls further on Makary comments | ||
| 27.02. | Moderna's combination flu, COVID shot wins over European drug regulators | ||
| 27.02. | Generate caps a strong month for biotech IPOs with $400M offering | ||
| 26.02. | Lilly's GLP-1 pill tops Novo's Rybelsus in head-to-head trial | ||
| 26.02. | Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer | ||
| 26.02. | Sarepta CEO Doug Ingram to retire, with company at a crossroads | ||
| 25.02. | Trump's State of the Union trumpets healthcare greatest hits, but no new policies | ||
| 25.02. | Alkermes' Richard Pops to step down after three-decade run as CEO | ||
| 25.02. | GSK to acquire 35Pharma in $950M deal for cardiovascular drug | ||
| 25.02. | 15 States sue HHS over changes to childhood vaccine schedule | ||
| 25.02. | With Vivtex deal, Novo gains a chance at better oral obesity drugs | ||
| 25.02. | BreezeBio banks $60M to make more precise genetic medicines | ||
| 24.02. | Vir climbs on Astellas deal, study results for 'masked' T cell engager |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.